Related Experiment Video
Updated: Aug 13, 2026
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Metformin: A Promising Candidate for Slowing the Progression of Cardiovascular Aging
Yan Miao1, Wenting Wang2, Ye Liu1
1Department of Endocrinology and Metabolism, the Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Aging and Disease
|August 11, 2026
Summary
Metformin shows potential for mitigating cardiovascular aging by targeting aging pathways. However, clinical evidence is mixed, necessitating larger trials to confirm its benefits in non-diabetic older adults.
Area of Science:
- Gerontology and Cardiovascular Medicine
- Pharmacology of Aging
Background:
- Cardiovascular aging involves endothelial dysfunction and arterial stiffening, increasing age-related cardiovascular disease risk.
- Metformin, a type 2 diabetes drug, is being investigated for its potential geroprotective effects.
- Its mechanisms may involve AMP-activated protein kinase activation and mitochondrial complex I inhibition.
Purpose of the Study:
- To evaluate metformin's efficacy in mitigating cardiovascular aging.
- To explore its underlying mechanisms and clinical evidence.
Main Methods:
- Review of preclinical data on metformin's effects on aging pathways (mitochondrial biogenesis, oxidative stress, autophagy, inflammation, epigenetics).
- Analysis of clinical evidence from observational studies and randomized controlled trials (RCTs).
Main Results:
- Preclinical studies show metformin targets fundamental aging pathways, suggesting cardiovascular benefits.
- Clinical trial results are heterogeneous, with some observational studies showing benefits and RCTs yielding inconsistent outcomes.
- Limitations include small sample sizes, short follow-up, and potential sex differences in response.
Conclusions:
- Metformin is a promising candidate for cardiovascular aging mitigation.
- Definitive conclusions require large-scale, long-term RCTs with aging biomarkers and sex/metabolic stratification.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:37Mitochondria
Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...